The study, published in the peer-reviewed journal BMC Public Health, analyzed longitudinal data from 490 participants in the long-running Vancouver Injection Drug Users Study, known as VIDUS, covering the period between March 2022 and February 2024. That window allowed researchers to compare experiences before the pilot began on January 31, 2023, with experiences during its first year of operation. Under the pilot, police in British Columbia were not meant to arrest or charge people for possessing drugs for personal consumption, with a possession threshold defined as 2.5 grams. The policy was framed as a three-year experiment in reducing the harms associated with criminalization, and its conclusion in January 2026 has only intensified scrutiny of what the evidence actually shows.

The headline finding is stark. Before the decriminalization pilot took effect, the quarterly prevalence of police drug seizure without arrest, regardless of the quantity of drugs a person possessed, ranged from 0.8 percent to 2.1 percent of study participants. During the pilot, that figure rose to between 1.1 percent and 4.1 percent. In other words, people in Vancouver reported experiencing more, not fewer, incidents in which police took their drugs away during the first year of a policy explicitly intended to reduce interaction between police and people who use drugs. Kanna Hayashi, co-author of the study and professor of health sciences at Simon Fraser University, who holds the St. Paul’s Hospital Chair in Substance Use Research, described the pattern as a significant upward trend of police drug seizures occurring without arrest.

The finding is particularly notable because it appears to diverge from officially reported police statistics. According to figures cited by the Vancouver Police Department, officers officially conducted zero possession seizures below the 2.5-gram threshold between February and October 2023. On paper, that would suggest the decriminalization framework was functioning as designed, with police stepping back from low-level possession enforcement. Yet the new study’s data, which are based on self-reports from people who use drugs rather than on police documentation, allow a different part of the picture to emerge. Hayashi explains that published police-reported statistics only account for events where officers documented an interaction as being related to drug possession, and those interactions may or may not have involved an arrest. Events that officers did not classify in that way would never appear in the official record.

This discrepancy between official statistics and community-reported experience is central to the study’s significance. Hayashi notes that her team’s data may overlap with police-reported figures in some places but likely captured events that did not go on to enter police records at all. Her conclusion is that each dataset is incomplete on its own, but that the two offer deeper insights when viewed together. For researchers and policymakers, this is a methodological lesson as much as a substantive one. Administrative data generated by the very institutions whose conduct is being evaluated can systematically miss the experiences of the people most affected by a policy. Self-reported data from cohorts such as VIDUS, which has followed people who use drugs in Vancouver for decades, provide an independent check on official narratives and can reveal patterns invisible in institutional records.

The consequences of drug seizures without arrest extend well beyond the loss of the substances themselves. The study found that participants who reported having drugs seized by police without arrest were three times more likely to experience a non-fatal overdose. Hayashi explains the mechanism in the context of the toxic drug-supply crisis that has claimed thousands of lives across British Columbia and Canada more broadly. In such a crisis, losing a drug supply can have serious consequences, she says. People may feel they need to replace those drugs immediately. If a person is rushing to obtain new drugs from an unknown source and then rushing to use them to avoid withdrawal symptoms, the risk of overdose increases. In an environment where the unregulated supply is already contaminated with variable and dangerous concentrations of synthetic opioids, any disruption that pushes someone toward an unfamiliar product or urgent use can be lethal.

Community researchers say the findings confirm what people with lived experience of drug use have been reporting for years. Scotty Archondous, a researcher-member at Police Oversight with Evidence and Research, known as P.O.W.E.R., and a board member of the Vancouver Area Network of Drug Users, or VANDU, says the study’s results align with concerns long raised by the community. As a community-based researcher across multiple projects, Archondous reports having heard directly from many people about their experiences of having their personal drug supply seized during decriminalization. The concern, as Archondous describes it, is that people who already live precariously face heightened risks when seizures occur without charges or arrest, because of what comes next: debts, desperation, and sometimes disrupted access to a trusted source. For people dependent on a regular supply, an unexpected seizure can cascade into unsafe borrowing, unsafe sourcing, or withdrawal-driven urgency.

The study also highlights a conceptual tension at the heart of the pilot’s design. Decriminalization removed the threat of arrest and prosecution for possession below the 2.5-gram threshold, but it did not remove police authority to seize drugs. An officer who cannot charge someone may still confiscate their substances, and from the perspective of the person on the street, the outcome, losing their supply, can be nearly identical to the outcome of the enforcement practices decriminalization was meant to replace. The data showing a rise in seizure reports without a corresponding rise in arrests suggest that the enforcement behavior adapted to the new legal framework rather than disappearing. Whether those seizures reflected officers exercising discretion in ambiguous situations, responding to public complaints, or operating under internal directives is a question the study’s data cannot fully answer, but the pattern itself is now documented with longitudinal rigor.

For Hayashi, the central takeaway is that data informed by people with lived experience must be viewed in tandem with official police statistics if policymakers want an accurate account of how decriminalization actually operated. Even though the pilot has ended, she argues that it is important to understand what happened and what can be improved, because those lessons can help shape future decriminalization policies in British Columbia and elsewhere. Jurisdictions considering similar approaches, from other Canadian provinces to cities and countries abroad, will be watching the British Columbia experiment closely. The study’s evidence suggests that the technical design of such policies matters enormously: thresholds, seizure powers, reporting requirements, and oversight mechanisms all shape whether decriminalization reduces police contact or merely changes its form.

The broader context makes these findings urgent. British Columbia’s decriminalization pilot was introduced amid a toxic drug-supply crisis that has driven historically high rates of overdose deaths, and the policy was one of the most prominent attempts in North America to treat drug use as a health issue rather than a criminal one. The pilot’s early end and the political controversy surrounding it have made rigorous evaluation all the more important. This study does not claim that decriminalization failed outright, nor does it conclude that police acted improperly; what it documents is a measurable gap between the policy’s stated goal of reducing police interaction with people who use drugs and the lived reality reported by a well-characterized cohort in Vancouver. It also quantifies a concrete harm, the tripling of non-fatal overdose risk among those whose drugs were seized, that any future policy framework will need to address directly. As Hayashi and her colleagues make clear, the value of the pilot lies in what can be learned from it, and those lessons are now on the record.

Subject of Research: Police drug seizures without arrest during British Columbia's drug decriminalization pilot in Vancouver

Article Title: Reports of drug seizures by police rose during first year of decriminalization, SFU study finds​

Article References: Reports of drug seizures by police rose during first year of decriminalization, SFU study finds​. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: drug decriminalization, British Columbia, Vancouver, police drug seizures, Simon Fraser University, BMC Public Health, overdose risk, toxic drug supply, VIDUS, harm reduction, drug policy, public health

The social-ecological framework, first articulated by developmental psychologist Urie Bronfenbrenner, holds that health decisions are never made in a vacuum. Instead, they emerge from interacting layers of influence: personal beliefs and motivations at the core, surrounded by family and peer networks, then the clinics and neighborhoods where people live, and finally the policies, laws and dominant social attitudes that govern treatment itself. The research team applied a modified version of this model to understand how recently incarcerated patients navigate a treatment landscape that has shifted dramatically in the past five years. Federal regulators have expanded take-home methadone doses, reducing the number of days patients must appear in person at an opioid treatment program, and removed the cap on how many patients a provider may prescribe buprenorphine to. Long-acting injectable buprenorphine has also entered the market, bringing its own barriers of cost and limited clinic availability.

Between March and August 2025, the team conducted semi-structured interviews averaging 50 minutes with adults who had received methadone or buprenorphine during an incarceration in the past year. Participants were recruited through opioid treatment programs, office-based providers and recovery centers across the state, with purposive efforts to balance representation by medication type. The sample, on average, had been released just over five months before the interview, was 37.6 years old on average, and included 16 men and 12 women. Most participants were White and non-Latino. At the time of interview, 25 of the 28 participants were receiving methadone and only three were on buprenorphine, even though most had received methadone during incarceration as well. Interviews were transcribed, coded using template-style thematic analysis with both deductive and inductive codes, and analyzed in NVivo until thematic saturation was achieved.

The first and most personal theme concerned perceived benefits. Participants continued MOUD when they felt it clearly worked — helping them avoid withdrawal, illicit opioid use and reincarceration, three outcomes that participants described as deeply intertwined. Many reported that methadone curbed their cravings more effectively than buprenorphine, a difference that proved decisive. One participant who could not reach a methadone clinic after release discontinued treatment entirely because buprenorphine, though easier to obtain with only monthly provider visits, did not adequately suppress his cravings; he resumed methadone only after moving closer to a clinic. This finding underscores a technical point with major clinical implications: patient preference is not merely about convenience but about pharmacological fit, and when the medication that works best is inaccessible, some patients opt for no medication at all.

Paradoxically, nearly all participants — even those who credited MOUD with stabilizing their recovery — expressed an intention to taper off within the next couple of years. Many described methadone or buprenorphine as a band-aid, a short-term tool rather than a chronic therapy, reflecting what the authors identify as an internalized abstinence narrative. This belief had concrete consequences for treatment selection: some participants rejected long-acting injectable buprenorphine precisely because its monthly dosing removed the daily control that would let them stop when they chose. The researchers argue that distinguishing between patients whose desire to discontinue is clinically congruent and those whose desire is driven by stigma or structural barriers is essential for designing interventions that improve retention during the highest-risk period.

At the interpersonal level, the study found that supportive family involvement was invaluable but rare. A few participants relied on relatives for transportation to daily methadone dosing, a logistical lifeline that made treatment feasible. Far more common was stigma within families, where methadone was perceived as simply swapping one drug for another. Several participants concealed their treatment from loved ones, describing it as embarrassing, and this concealment bred isolation. In one striking account, a participant who had been stable after a previous release — employed, housed, engaged in methadone treatment — stopped the medication because of his mother’s disapproval, relapsed into illicit opioid use, and experienced worsening mental health. Others deliberately shrank their social circles to avoid substance use triggers or exposure. Against this backdrop, many participants emphasized self-reliance, framing their recovery as something they had to accomplish alone, and some even preferred buprenorphine’s relative lack of wraparound services because it demanded less dependence on institutions.

Community and organizational factors proved to be powerful levers of access. Housing proximity to an opioid treatment program, access to a working vehicle, and reliable bus routes determined whether daily methadone dosing was realistic. Free transportation services funded through public insurance helped some participants, but others were unaware of these programs, lost passes, or found multi-bus commutes prohibitive. One woman who had to make lengthy near-daily trips by bus concluded that methadone simply did not work for someone without a car and expressed regret over starting it during incarceration, saying she would prefer a monthly injectable so she would not have to worry about dosing every day. The physical environment around clinics also mattered: visible drug activity near treatment sites triggered discomfort and cravings for some patients, deterring them from clinics even when those clinics were close to home.

Clinic practices themselves shaped treatment trajectories. Participants described anxiety over whether they could receive same-day dosing at community intake, hearsay about waitlists, unclear urine drug screening policies, and fear of missing doses when entering residential programs. Although no participant experienced significant gaps in care after reaching a clinic, the psychological cost of fearing withdrawal was real, and for some it motivated a desire to taper off entirely. One participant, facing a warned urine drug screen from his buprenorphine prescriber shortly after release, chose to stop treatment and continue using before later switching to methadone. These accounts illustrate how restrictive or opaque clinic rules can convert a treatable condition into a cycle of disengagement, use and re-engagement.

At the structural level, the fentanyl-dominant drug supply emerged as a decisive force. Participants who were still using opioids feared precipitated withdrawal if they initiated buprenorphine with fentanyl in their system, rendering buprenorphine and its injectable formulation non-viable options in their eyes. Methadone, by contrast, was seen as robust in the fentanyl era, though a few participants described developing a double habit — concurrent methadone and illicit fentanyl use that pushed their methadone doses upward and left them uncomfortable if either substance was unavailable. Methadone also carried a unique legal advantage: its mandatory counseling satisfied probation requirements for some participants, helping them avoid re-arrest, a benefit no buprenorphine recipient reported. Meanwhile, expanded take-home methadone policies motivated engagement for some, but patients with instability indicators often could not accrue take-homes quickly enough, and the threat of losing privileges after hospitalization or reincarceration discouraged others. Systemic stigma in employment and housing further eroded commitment, with participants questioning whether they could be hired as nurses or in other careers while on methadone.

The authors conclude that MOUD preferences and intentions after incarceration are entangled with multilevel barriers, and that improving retention will require interventions at every layer: pre-release education to counter misinformation and stigma, stronger linkage to MOUD-affirming recovery communities and peer support specialists, transportation solutions, and lower-barrier delivery models including community-based post-release dosing. Peer support specialists were described as helpful by the few participants who encountered them, but their scarcity reflects the slow integration of these roles into treatment systems. Given that discontinuing MOUD sharply elevates overdose risk, particularly when cessation occurs early, the stakes of preference-congruent care could not be higher. This study offers a detailed, patient-centered map of why people leaving incarceration choose, keep or abandon their medications — knowledge the authors say is essential for building treatment systems that keep people alive through the perilous transition home.

Subject of Research: Social-ecological determinants of medication preferences and receipt for opioid use disorder after incarceration

Article Title: Social-ecological factors shape preferences for and receipt of medications to treat opioid use disorder in the post-incarceration period

Article References: Bailey, A., Hughto, J. M., Kelly, P. J., Dunsiger, S. I., & Martin, R. A. (2026). Social-ecological factors shape preferences for and receipt of medications to treat opioid use disorder in the post-incarceration period. SSM – Mental Health, 10, Article 100705. https://doi.org/10.1016/j.ssmmh.2026.100705

Image Credits: AI Generated

DOI: 10.1016/j.ssmmh.2026.100705

Keywords: opioid use disorder, methadone, buprenorphine, post-incarceration, social-ecological model, stigma, overdose risk, fentanyl, opioid treatment programs, peer support, reentry, qualitative research